Basilea Pharmaceutica Ag

Basilea Pharmaceuticals Ag

Eric Desarbre

Malcolm G P Page

Patrick Roussel

Bérangère Gaucher

Malcom G P Page

Bérangére Gaucher

Malcolm GP Page

A pharmaceutical composition, comprising a combination of an antibiotically active compound of the formula (I): with a &#x3b2;-lactamase inhibitor of one of the formulae (II) to (XIII) are active against Gram-negative bacteria, in particular such bacteria which have become resistant against antibiotics such as aztreonam, carumonam and tigemonam. Optionally the compositions may comprise another &#x3b2;-lactamase inhibitor of one of the formulae (II) to (XIII), particularly of formula (V) or formula (VI).

Useful combinations of monobactam antibiotics with beta-lactamase inhibitors

New monobactam antibiotics compounds which contain an 3-amino-azetidin-2-one ring and are active against gram-negative bacteria, wherein the compounds include the compound 2-(2-amino-thiazol-4-yl)-2-[(Z)-(1H,4H-1,5-dihydroxy-4-oxo-pyridin-2-yl)methoxyimino]-N-[3(S)-1-oxysulfonyl-2,2-dimethyl-4-oxo-azetidin-3-yl]acetamide.

Use of a monobactam antibiotic of formula (I) wherein the oxyimino group i.e. &#x3e;C&#x2550;N&#x2014;O&#x2014; has Z-orientation, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a bacterial infection in combination with a carbapenem antibiotic or a pharmaceutically acceptable salt thereof.

Growing community of inventors

Mulhouse, France

Eric Desarbre